Aligos Therapeutics (ALGS)
Market Price (5/10/2026): $6.43 | Market Cap: $66.9 MilSector: Health Care | Industry: Biotechnology
Aligos Therapeutics (ALGS)
Market Price (5/10/2026): $6.43Market Cap: $66.9 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -75% Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 44% Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -68% Megatrend and thematic driversMegatrends include Precision Medicine. Themes include Biopharmaceutical R&D, and Targeted Therapies. | Weak multi-year price returns2Y Excs Rtn is -112%, 3Y Excs Rtn is -161% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -96 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -2033% Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -11% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 115% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -1801%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -1811% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -139% Key risksALGS key risks include [1] its heavy dependence on the success of unproven, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -75% |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 44% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -68% |
| Megatrend and thematic driversMegatrends include Precision Medicine. Themes include Biopharmaceutical R&D, and Targeted Therapies. |
| Weak multi-year price returns2Y Excs Rtn is -112%, 3Y Excs Rtn is -161% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -96 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -2033% |
| Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -11% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 115% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -1801%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -1811% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -139% |
| Key risksALGS key risks include [1] its heavy dependence on the success of unproven, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Aligos Therapeutics (ALGS) stock has lost about 20% since 1/31/2026 because of the following key factors:
1. Persistent Cash Burn and Funding Uncertainty Weighing on Future Operations.
Despite Aligos Therapeutics securing an exclusive licensing deal in April 2026 with Xiamen Amoytop Biotech Co., Ltd. for its hepatitis B drug candidate, pevifoscorvir sodium, which included a $25 million upfront payment and potential milestones of up to $420 million, the company's cash runway is still projected to extend only into the second half of 2026. This continued need for further equity issuance to fund ongoing Phase 2b and Phase 3 clinical activities creates investor concern regarding potential dilution and the company's long-term financial stability. Aligos' stock declined by 35.3% from January 1, 2026, to May 7, 2026, falling from $9.32 to $6.03, reflecting this underlying investor apprehension.
2. Extended Timelines and Increased Costs for Key Clinical Program.
In April 2026, Aligos announced results from the first interim analysis of its Phase 2 B-SUPREME study for pevifoscorvir sodium in chronic hepatitis B virus (HBV) infection. While the Drug Safety Monitoring Board (DSMB) recommended continuing the trial and did not find futility criteria were met, they advised increasing the sample size of the HBeAg- cohort from 74 to 100 participants. This recommendation, while aimed at strengthening statistical power, implies a longer and potentially more expensive clinical trial, pushing the expectation for definitive topline data further into 2027. This extended timeline for a pivotal readout can lead to investor impatience and increased uncertainty.
Show more
1. Persistent Cash Burn and Funding Uncertainty Weighing on Future Operations.
Despite Aligos Therapeutics securing an exclusive licensing deal in April 2026 with Xiamen Amoytop Biotech Co., Ltd. for its hepatitis B drug candidate, pevifoscorvir sodium, which included a $25 million upfront payment and potential milestones of up to $420 million, the company's cash runway is still projected to extend only into the second half of 2026. This continued need for further equity issuance to fund ongoing Phase 2b and Phase 3 clinical activities creates investor concern regarding potential dilution and the company's long-term financial stability. Aligos' stock declined by 35.3% from January 1, 2026, to May 7, 2026, falling from $9.32 to $6.03, reflecting this underlying investor apprehension.
2. Extended Timelines and Increased Costs for Key Clinical Program.
In April 2026, Aligos announced results from the first interim analysis of its Phase 2 B-SUPREME study for pevifoscorvir sodium in chronic hepatitis B virus (HBV) infection. While the Drug Safety Monitoring Board (DSMB) recommended continuing the trial and did not find futility criteria were met, they advised increasing the sample size of the HBeAg- cohort from 74 to 100 participants. This recommendation, while aimed at strengthening statistical power, implies a longer and potentially more expensive clinical trial, pushing the expectation for definitive topline data further into 2027. This extended timeline for a pivotal readout can lead to investor impatience and increased uncertainty.
Show more
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The -20.3% change in ALGS stock from 1/31/2026 to 5/10/2026 was primarily driven by a -55.0% change in the company's P/S Multiple.| (LTM values as of) | 1312026 | 5102026 | Change |
|---|---|---|---|
| Stock Price ($) | 8.07 | 6.43 | -20.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 3 | 5 | 77.8% |
| P/S Multiple | 31.6 | 14.2 | -55.0% |
| Shares Outstanding (Mil) | 10 | 10 | -0.3% |
| Cumulative Contribution | -20.3% |
Market Drivers
1/31/2026 to 5/10/2026| Return | Correlation | |
|---|---|---|
| ALGS | -20.2% | |
| Market (SPY) | 3.6% | 35.1% |
| Sector (XLV) | -6.9% | 21.7% |
Fundamental Drivers
The -22.1% change in ALGS stock from 10/31/2025 to 5/10/2026 was primarily driven by a -47.2% change in the company's P/S Multiple.| (LTM values as of) | 10312025 | 5102026 | Change |
|---|---|---|---|
| Stock Price ($) | 8.25 | 6.43 | -22.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 3 | 5 | 48.2% |
| P/S Multiple | 26.9 | 14.2 | -47.2% |
| Shares Outstanding (Mil) | 10 | 10 | -0.5% |
| Cumulative Contribution | -22.1% |
Market Drivers
10/31/2025 to 5/10/2026| Return | Correlation | |
|---|---|---|
| ALGS | -21.9% | |
| Market (SPY) | 5.5% | 17.9% |
| Sector (XLV) | 0.3% | 18.0% |
Fundamental Drivers
The 15.2% change in ALGS stock from 4/30/2025 to 5/10/2026 was primarily driven by a 60.0% change in the company's P/S Multiple.| (LTM values as of) | 4302025 | 5102026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.58 | 6.43 | 15.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 4 | 5 | 19.3% |
| P/S Multiple | 8.9 | 14.2 | 60.0% |
| Shares Outstanding (Mil) | 6 | 10 | -39.6% |
| Cumulative Contribution | 15.2% |
Market Drivers
4/30/2025 to 5/10/2026| Return | Correlation | |
|---|---|---|
| ALGS | 15.4% | |
| Market (SPY) | 30.4% | 29.1% |
| Sector (XLV) | 4.0% | 28.2% |
Fundamental Drivers
The -77.8% change in ALGS stock from 4/30/2023 to 5/10/2026 was primarily driven by a -83.5% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 4302023 | 5102026 | Change |
|---|---|---|---|
| Stock Price ($) | 29.00 | 6.43 | -77.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 14 | 5 | -66.2% |
| P/S Multiple | 3.6 | 14.2 | 297.9% |
| Shares Outstanding (Mil) | 2 | 10 | -83.5% |
| Cumulative Contribution | -77.8% |
Market Drivers
4/30/2023 to 5/10/2026| Return | Correlation | |
|---|---|---|
| ALGS | -77.8% | |
| Market (SPY) | 78.7% | 26.6% |
| Sector (XLV) | 13.0% | 16.4% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| ALGS Return | -57% | -92% | -30% | 140% | -77% | -35% | -99% |
| Peers Return | -14% | 71% | 17% | 20% | 98% | 1% | 312% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 7% | 95% |
Monthly Win Rates [3] | |||||||
| ALGS Win Rate | 50% | 25% | 25% | 50% | 33% | 40% | |
| Peers Win Rate | 45% | 45% | 40% | 48% | 57% | 48% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 60% | |
Max Drawdowns [4] | |||||||
| ALGS Max Drawdown | -58% | -92% | -41% | -58% | -90% | -36% | |
| Peers Max Drawdown | -26% | -34% | -29% | -26% | -28% | -17% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: MDGL, GILD, IONS, ARWR, VKTX.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 5/8/2026 (YTD)
How Low Can It Go
| Event | ALGS | S&P 500 |
|---|---|---|
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -12.3% | -7.8% |
| % Gain to Breakeven | 14.0% | 8.5% |
| Time to Breakeven | 1 days | 18 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -39.8% | -9.5% |
| % Gain to Breakeven | 66.0% | 10.5% |
| Time to Breakeven | 78 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -42.5% | -6.7% |
| % Gain to Breakeven | 73.9% | 7.1% |
| Time to Breakeven | 629 days | 31 days |
In The Past
Aligos Therapeutics's stock fell -12.3% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 14.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | ALGS | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -39.8% | -9.5% |
| % Gain to Breakeven | 66.0% | 10.5% |
| Time to Breakeven | 78 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -42.5% | -6.7% |
| % Gain to Breakeven | 73.9% | 7.1% |
| Time to Breakeven | 629 days | 31 days |
In The Past
Aligos Therapeutics's stock fell -12.3% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 14.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Aligos Therapeutics (ALGS)
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.
AI Analysis | Feedback
Here are 1-2 brief analogies for Aligos Therapeutics:
An early-stage Gilead Sciences, specializing in developing new treatments for chronic hepatitis B and fatty liver disease.
A biotech startup focused on discovering breakthrough drugs for liver and viral diseases, much like a young Vertex Pharmaceuticals before its major successes in specific disease areas.
AI Analysis | Feedback
- ALG-010133: An oligonucleotide polymer designed to inhibit s-antigen transport for chronic hepatitis B.
- ALG-000184: A capsid assembly modulator in development for chronic hepatitis B.
- ALG-020572: An antisense oligonucleotide aimed at preventing HBsAg translation and secretion.
- ALG-055009: A small molecule THR-ß agonist targeting non-alcoholic steatohepatitis (NASH).
- ALG-125755: An siRNA drug candidate developed to inhibit HBsAg release.
- ALG-125097 and ALG-125819: Drug candidates designed to potently inhibit HBsAg release from HBV-infected cells.
AI Analysis | Feedback
Aligos Therapeutics, Inc. (ALGS) is a clinical-stage biopharmaceutical company focused on developing novel therapeutics. As such, it does not currently have commercial products on the market sold to individuals or traditional customers.
Instead, its major "customers" or revenue sources come from strategic collaborations and licensing agreements with other companies and institutions that provide funding, research support, and rights for future commercialization of its drug candidates and technologies. Based on the provided description, these include:
- Luxna Biotech Co., Ltd. (Private company)
- Emory University (Academic institution)
- Katholieke Universiteit Leuven (Academic institution)
- Merck (Public company, symbol:
MRK) - *Correction: Merck & Co., Inc. symbol is MRK.*
AI Analysis | Feedback
nullAI Analysis | Feedback
Lawrence M. Blatt, Ph. D., M.B.A. Chief Executive Officer Dr. Blatt co-founded Aligos Therapeutics and has served as its Chief Executive Officer and a member of the board of directors since February 2018. He is a serial biotech entrepreneur who co-founded Alios BioPharma, Inc., serving as its Chief Executive Officer, President, and Director from January 2009 until its acquisition by Johnson & Johnson in November 2014 for $1.75 billion. Prior to Alios, he was Chief Scientific Officer of InterMune, Inc., which was acquired by Roche in 2014. He also served as the Global Head of Infectious Diseases and Vaccines at Janssen Pharmaceutical Companies of Johnson & Johnson from November 2014 to February 2018. Dr. Blatt also co-founded and is Chairman of the Board of Directors for Alveo Diagnostics. He is the recipient of the Ernst & Young Entrepreneur of the Year Award in the life science category. Lesley Ann Calhoun Executive Vice President, Chief Operating Officer, and Chief Financial Officer Ms. Calhoun has served as Aligos' Executive Vice President, Chief Financial Officer since June 2020. She is an experienced finance executive with 17 years in the biopharma industry, with an earlier career in U.S. and multinational technology companies and public accounting. Prior to joining Aligos, Ms. Calhoun was Senior Vice President of Finance & Administration and Chief Accounting Officer at Global Blood Therapeutics (GBT). At GBT, she was responsible for the finance, accounting, and administrative functions, supporting the company's transition from a clinical stage to a publicly traded, commercial environment, and was involved in the successful regulatory approval and commercial launch of Oxbryta®. She also served as Vice President of Finance at Hyperion Therapeutics Inc., where she played a key role in building the finance infrastructure that led to the successful commercialization of RAVICTI®. Ms. Calhoun has served as a Director of Tango Therapeutics, Inc., a publicly traded biotechnology company, since March 2021, and is the Chair of the Audit Committee and a member of the Nominating and Corporate Governance Committee. Sushmita M. Chanda, Ph. D. Executive Vice President, Chief Development Officer Dr. Chanda serves as Aligos' Executive Vice President and Chief Development Officer. Before joining Aligos, she was Vice President, Preclinical Development at Alios BioPharma, Inc., from February 2010 to July 2018, until its acquisition by Janssen Pharmaceutical Companies of Johnson & Johnson. From 2000 to 2010, Dr. Chanda held various roles of increasing responsibilities at F. Hoffman-La Roche Ltd, including Senior Director and Head of Nonclinical Safety. James Hassard, MBA Executive Vice President, Chief Commercial Officer Mr. Hassard was appointed Executive Vice President, Chief Commercial Officer, effective January 13, 2026. In this role, he will lead and build the company's global commercial capabilities and serve as a member of Aligos' Senior Leadership Team. He is a seasoned executive with extensive experience building commercial organizations across multiple therapeutic areas. Prior to Aligos, Mr. Hassard was Chief Commercial Officer at Crinetics Pharmaceuticals and Arrowhead Pharmaceuticals, where he developed commercial capabilities and launch strategies for over four rare disease programs. His career also includes positions of increasing responsibility at Coherus Oncology, Amgen, and Merck, with global experience in the U.S., Canada, and Europe, where he launched pharmaceutical products in therapeutic areas such as hepatitis, oncology, and nephrology. Hardean Achneck, M.D. Chief Medical Officer Dr. Achneck has been appointed as Aligos' Chief Medical Officer, effective immediately. He spearheads the company's global clinical development initiatives and is a member of the Senior Leadership Team. Dr. Achneck possesses extensive experience in clinical development across various therapeutic areas, including hepatology and infectious diseases. Before joining Aligos, he was Vice President of Clinical Development at Dicerna Therapeutics, which was acquired by Novo Nordisk in 2021. He continued to lead efforts within the Novo Nordisk Dicerna Transformational Research Unit, focusing on liver-targeted therapies like xalnesiran for chronic hepatitis B. Prior to his biopharmaceutical industry career, Dr. Achneck was an Assistant Professor of Surgery and Pathology at Duke University School of Medicine, and also held a joint appointment as Assistant Professor of Cardiovascular & Metabolic Disorders at Duke-National University of Singapore.AI Analysis | Feedback
The key risks to Aligos Therapeutics (ALGS) are primarily related to its financial viability, the inherent challenges of drug development, and intense competition in its target therapeutic areas.
-
Financial Health and Going Concern Risk: Aligos Therapeutics faces significant financial challenges, with reported negative operating and net margins and a low cash runway. Management has expressed substantial doubt about the company's ability to continue as a going concern without securing additional financing, as existing funds are expected to last only into the third quarter of 2026. This indicates a critical need for further capital to sustain operations and ongoing drug development programs.
-
Clinical Development and Regulatory Approval Risk: As a clinical-stage biopharmaceutical company, Aligos' future success is highly dependent on the successful outcome of its drug candidates in clinical trials and their ability to gain regulatory approval. The company's lead candidates, such as ALG-010133, ALG-000184 (pevifoscorvir sodium), ALG-020572, and ALG-055009, are in early to mid-stage clinical trials (Phase Ib, Phase I, Phase 1a/1b, Phase 2), and there is no guarantee that they will demonstrate sufficient efficacy or safety, or ultimately receive marketing authorization.
-
Competition: Aligos Therapeutics operates in highly competitive therapeutic areas, including chronic hepatitis B (CHB) and non-alcoholic steatohepatitis (NASH). Numerous other pharmaceutical and biotechnology companies are actively developing or marketing competing therapies for these conditions. Aligos' drug candidates, particularly ALG-055009 for NASH, are positioned in a "competitively challenged" landscape. The company's ability to differentiate its products and secure market share against existing and emerging treatments is a significant risk.
AI Analysis | Feedback
nullAI Analysis | Feedback
Aligos Therapeutics (ALGS) focuses on developing novel therapeutics for viral and liver diseases, with lead drug candidates targeting Chronic Hepatitis B (CHB) and Non-alcoholic Steatohepatitis (NASH). The addressable markets for these main products are substantial globally and in key regions.
Chronic Hepatitis B (CHB)
- The global chronic hepatitis B market was valued at approximately USD 2,709.4 million in 2023 and is projected to reach USD 3,379.3 million by 2034.
- The Chronic Hepatitis B therapeutics market across the seven major markets (7MM), which include the U.S., EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, is forecast to grow from USD 1.5 billion in 2024 to USD 3.2 billion by 2034.
- In 2024, the U.S. alone represented the largest market for CHB within the 7MM, with sales of USD 710.11 million. The U.S. Hepatitis B Treatment Market is projected to grow from USD 1.00 billion in 2025 to USD 1.54 billion by 2033.
Non-alcoholic Steatohepatitis (NASH)
- The global NASH drugs market was valued at USD 5.7 billion in 2024, is projected to reach USD 7.7 billion in 2025, and is expected to grow significantly to USD 78.2 billion by 2035.
- Another estimate places the global non-alcoholic steatohepatitis treatment market size at USD 7.72 billion in 2024, with a projection to reach USD 33.80 billion by 2030. Similarly, the global non-alcoholic steatohepatitis treatment market size was calculated at USD 7.75 billion in 2024 and is projected to reach around USD 92.5 billion by 2034.
- North America dominated the global non-alcoholic steatohepatitis treatment market, accounting for a 79.12% share in 2024. The U.S. non-alcoholic steatohepatitis treatment market was valued at USD 4.56 billion in 2024 and is expected to reach USD 32.55 billion by 2032. In 2023, the U.S. NASH market was approximately USD 1,519 million.
AI Analysis | Feedback
Here are 3-5 expected drivers of future revenue growth for Aligos Therapeutics (ALGS) over the next 2-3 years:- Milestone Payments from Existing Collaboration Agreements: Aligos Therapeutics stands to generate revenue through milestone payments from its existing license and collaboration agreements. Specifically, the company has an agreement with Merck for the discovery and development of oligonucleotide therapies for non-alcoholic steatohepatitis (NASH) and up to one additional cardiometabolic/fibrosis target. Under this collaboration, Aligos is eligible for development and commercialization milestones that could reach up to $458 million to $460 million, in addition to tiered royalties on net sales. Furthermore, its partnership with Xiamen Amoytop Biotech Co. for ALG-170675, a dual-mechanism antisense oligonucleotide for chronic hepatitis B (CHB), involves Amoytop funding development costs in China and advancing the candidate into IND-enabling studies, which could trigger additional milestone payments to Aligos.
- New Partnership for ALG-055009 (Obesity/MASH): Aligos is actively pursuing a partnership for its small molecule THR-β agonist, ALG-055009, which is being developed for obesity and metabolic dysfunction-associated steatohepatitis (MASH). Recent preclinical data demonstrating significant synergistic weight loss when ALG-055009 is combined with incretin therapies (like GLP-1s) has substantially enhanced its commercial appeal beyond MASH, potentially accelerating discussions for a lucrative out-licensing deal. Such a new collaboration could provide Aligos with upfront payments, development milestones, and future royalties, contributing significantly to its revenue growth. The company has expressed enthusiasm and is in "continued discussions with potential partners for obesity and MASH" for ALG-055009.
- Advancement and Potential Monetization of Chronic Hepatitis B (CHB) Pipeline: The progression of Aligos' lead CHB drug candidate, pevifoscorvir sodium (ALG-000184), is a crucial driver. The Phase 2 B-SUPREME study for pevifoscorvir sodium has completed planned enrollment for the HBeAg- cohort and is continuing enrollment for the HBeAg+ cohort, with interim analyses expected in the first and second half of 2026, and topline data anticipated in 2027. Positive clinical trial readouts are essential to attracting new partners or expanding existing collaborations for the CHB program, which could lead to further milestone payments or new licensing agreements. The company believes pevifoscorvir sodium may impact key aspects of HBV disease pathogenesis (replication, integration, and viral reservoir maintenance).
AI Analysis | Feedback
```htmlShare Issuance
- Aligos Therapeutics completed a public offering in June 2021, issuing 4,400,000 shares of common stock at $19.00 per share, generating gross proceeds of approximately $83.6 million.
- In March 2026, a registration statement was filed for the issuance of 519,783 shares of common stock under the 2020 Incentive Award Plan and 61,782 shares under the 2020 Employee Stock Purchase Plan.
- In January 2026, the company granted non-qualified stock options for an aggregate of 81,100 shares to newly hired employees as inducement grants.
Inbound Investments
- Aligos Therapeutics has raised a total of $225 million across four funding rounds.
- Cash, cash equivalents, and investments totaled $77.8 million as of December 31, 2025, which is expected to provide sufficient funding into the third quarter of 2026.
Capital Expenditures
- In the 12 months leading up to March 2026, capital expenditures amounted to -$437,000.
- The company invested $7K in capital expenditures in Q1 2023, primarily to fund long-term assets and infrastructure.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Aligos Therapeutics Earnings Notes | 12/16/2025 | |
| 9-Day Rally Sends Aligos Therapeutics Stock Up 62% | 11/27/2025 | |
| Aligos Therapeutics Stock Rockets 57% With 7-Day Winning Streak | 11/26/2025 | |
| Aligos Therapeutics Stock Rockets 59% With 8-Day Winning Streak | 11/26/2025 | |
| Can Aligos Therapeutics Stock Recover If Markets Fall? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to ALGS.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 04302026 | GEHC | GE HealthCare Technologies | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | IQV | IQVIA | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | UHS | Universal Health Services | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ABT | Abbott Laboratories | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ZBIO | Zenas BioPharma | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 74.82 |
| Mkt Cap | 11.5 |
| Rev LTM | 840 |
| Op Inc LTM | -268 |
| FCF LTM | -179 |
| FCF 3Y Avg | -173 |
| CFO LTM | -176 |
| CFO 3Y Avg | -129 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 43.9% |
| Rev Chg 3Y Avg | 14.1% |
| Rev Chg Q | 87.0% |
| QoQ Delta Rev Chg LTM | 12.1% |
| Op Inc Chg LTM | -0.5% |
| Op Inc Chg 3Y Avg | -3.9% |
| Op Mgn LTM | -33.3% |
| Op Mgn 3Y Avg | -257.0% |
| QoQ Delta Op Mgn LTM | 3.6% |
| CFO/Rev LTM | -23.7% |
| CFO/Rev 3Y Avg | -152.8% |
| FCF/Rev LTM | -24.0% |
| FCF/Rev 3Y Avg | -257.9% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 11.5 |
| P/S | 13.1 |
| P/Op Inc | -21.3 |
| P/EBIT | -29.4 |
| P/E | -21.3 |
| P/CFO | -12.2 |
| Total Yield | -2.8% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -4.7% |
| D/E | 0.1 |
| Net D/E | -0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -3.7% |
| 3M Rtn | -2.7% |
| 6M Rtn | 3.6% |
| 12M Rtn | 58.4% |
| 3Y Rtn | 80.8% |
| 1M Excs Rtn | -13.5% |
| 3M Excs Rtn | -9.4% |
| 6M Excs Rtn | -4.6% |
| 12M Excs Rtn | 27.7% |
| 3Y Excs Rtn | -5.9% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Discovering and developing drug candidates in both liver and viral diseases | 4 | 16 | 14 | 4 | |
| Total | 4 | 16 | 14 | 4 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Discovering and developing drug candidates in both liver and viral diseases | -131 | -88 | |||
| Total | -131 | -88 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Discovering and developing drug candidates in both liver and viral diseases | 265 | ||||
| Total | 265 |
Price Behavior
Price Behavior
| Market Price | $6.44 | |
| Market Cap ($ Bil) | 0.1 | |
| First Trading Date | 10/16/2020 | |
| Distance from 52W High | -51.6% | |
| 50 Days | 200 Days | |
| DMA Price | $7.03 | $8.53 |
| DMA Trend | down | down |
| Distance from DMA | -8.5% | -24.5% |
| 3M | 1YR | |
| Volatility | 75.7% | 85.4% |
| Downside Capture | 0.26 | 0.42 |
| Upside Capture | -17.80 | 101.09 |
| Correlation (SPY) | 29.8% | 28.8% |
ALGS Betas & Captures as of 4/30/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 2.25 | 1.40 | 1.84 | 1.20 | 2.13 | 1.83 |
| Up Beta | 2.34 | 2.48 | 3.38 | 3.13 | 4.08 | 1.61 |
| Down Beta | -0.20 | 2.36 | 3.25 | 1.91 | 2.32 | 2.43 |
| Up Capture | 36% | 24% | 25% | -12% | 112% | 149% |
| Bmk +ve Days | 15 | 22 | 31 | 66 | 141 | 428 |
| Stock +ve Days | 13 | 24 | 32 | 62 | 133 | 351 |
| Down Capture | 528% | 99% | 134% | 65% | 115% | 112% |
| Bmk -ve Days | 4 | 18 | 30 | 56 | 108 | 321 |
| Stock -ve Days | 9 | 19 | 32 | 63 | 117 | 383 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ALGS | |
|---|---|---|---|---|
| ALGS | 44.2% | 90.2% | 0.80 | - |
| Sector ETF (XLV) | 7.9% | 15.4% | 0.30 | 30.4% |
| Equity (SPY) | 29.0% | 12.5% | 1.83 | 29.5% |
| Gold (GLD) | 39.8% | 27.0% | 1.22 | -3.6% |
| Commodities (DBC) | 50.6% | 18.0% | 2.21 | -3.2% |
| Real Estate (VNQ) | 13.0% | 13.5% | 0.66 | 17.5% |
| Bitcoin (BTCUSD) | -17.4% | 42.1% | -0.34 | 20.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ALGS | |
|---|---|---|---|---|
| ALGS | -60.9% | 99.7% | -0.47 | - |
| Sector ETF (XLV) | 4.9% | 14.6% | 0.16 | 15.7% |
| Equity (SPY) | 12.8% | 17.1% | 0.59 | 24.9% |
| Gold (GLD) | 20.9% | 17.9% | 0.95 | 1.1% |
| Commodities (DBC) | 13.8% | 19.1% | 0.59 | 5.0% |
| Real Estate (VNQ) | 3.4% | 18.8% | 0.08 | 15.5% |
| Bitcoin (BTCUSD) | 7.0% | 56.0% | 0.34 | 18.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ALGS | |
|---|---|---|---|---|
| ALGS | -33.5% | 100.5% | -0.26 | - |
| Sector ETF (XLV) | 9.3% | 16.5% | 0.46 | 15.4% |
| Equity (SPY) | 15.1% | 17.9% | 0.72 | 23.6% |
| Gold (GLD) | 13.4% | 15.9% | 0.69 | 0.1% |
| Commodities (DBC) | 9.3% | 17.8% | 0.44 | 4.5% |
| Real Estate (VNQ) | 5.8% | 20.7% | 0.24 | 14.6% |
| Bitcoin (BTCUSD) | 67.8% | 66.9% | 1.07 | 17.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 3/5/2026 | -2.9% | 10.3% | 16.2% |
| 11/6/2025 | -3.1% | -11.9% | 47.1% |
| 8/6/2025 | 1.1% | -4.9% | 41.0% |
| 3/10/2025 | -19.6% | -11.6% | -61.0% |
| 11/6/2024 | 6.1% | 109.4% | 206.6% |
| 8/6/2024 | 21.9% | 20.6% | 6.8% |
| 3/12/2024 | 0.0% | 7.1% | 21.8% |
| 11/2/2023 | 1.4% | 2.7% | -9.3% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 8 | 9 | 8 |
| # Negative | 8 | 7 | 8 |
| Median Positive | 5.6% | 9.0% | 22.1% |
| Median Negative | -2.9% | -4.9% | -16.4% |
| Max Positive | 21.9% | 109.4% | 206.6% |
| Max Negative | -19.6% | -16.5% | -61.0% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/07/2026 | 10-Q |
| 12/31/2025 | 03/05/2026 | 10-K |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/06/2025 | 10-Q |
| 03/31/2025 | 05/06/2025 | 10-Q |
| 12/31/2024 | 03/10/2025 | 10-K |
| 09/30/2024 | 11/06/2024 | 10-Q |
| 06/30/2024 | 08/06/2024 | 10-Q |
| 03/31/2024 | 05/07/2024 | 10-Q |
| 12/31/2023 | 03/12/2024 | 10-K |
| 09/30/2023 | 11/02/2023 | 10-Q |
| 06/30/2023 | 08/03/2023 | 10-Q |
| 03/31/2023 | 05/04/2023 | 10-Q |
| 12/31/2022 | 03/09/2023 | 10-K |
| 09/30/2022 | 11/02/2022 | 10-Q |
| 06/30/2022 | 08/04/2022 | 10-Q |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.